Bayer
Bayer to buy Steigerwald
May 21, 2013Sales and Marketing Bayer, steigerwald
Bayer is to buy herbal medicines specialist Steigerwald Arzneimittelwerk in a deal which it says is motivated in part by …
German regulator assesses more drugs
April 22, 2013Sales and Marketing AMNOG, Bayer, Germany, Pradaxa, Xarelto
A new raft of drugs which will be subject to potentially stringent cost/benefit analysis in Germany has been announced. The …
Xarelto gets EU nod
March 25, 2013Sales and Marketing Bayer, Xarelto
Bayer HealthCare has been given a boost by the recommendation in Europe of its oral blood thinner Xarelto to prevent …
New AF possibility for Xarelto
March 11, 2013Sales and Marketing Bayer, FDA, Xarelto
Bayer HealthCare is to launch a new trial of its oral blood thinner Xarelto just days after the FDA knocked …
£20m research boost for Scottish biotech
February 11, 2013Research and Development, Sales and Marketing Bayer, BioCity Scotland, Dundee, EFPIA
BioCity Scotland and the University of Dundee are to play key roles in a newly-launched pan-European drug discovery project. In …
Bayer/Janssen seek Xa inhibitor antidote
February 6, 2013Research and Development, Sales and Marketing Bayer, Janssen, PRT4445, Xarelto
Bayer HealthCare and Janssen Pharmaceuticals have signed a deal with Portola Pharmaceuticals to evaluate the safety of an investigational antidote …
Jörg Reinhardt to leave Bayer for Novartis
January 24, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Novartis, Reinhardt
The chairman of the Board and member of the Bayer executive council Dr Jörg Reinhard is stepping down from his …
Bayer cleared of Xarelto ‘breaches’
January 17, 2013Medical Communications, Sales and Marketing Bayer, PMCPA, Xarelto
Bayer has been found not guilty of making multiple breaches of the ABPI Code of Practice following an anonymous complaint …
New price and data changes NICE view on Lucentis
January 4, 2013Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis
A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …
New boost for drug candidates
December 5, 2012Research and Development, Sales and Marketing Bayer, EFPIA, K4DD, Leiden
A new project is trying to increase the hit rates of successful drug candidates by improving the way they are …
Pharmacos ink green manufacturing pact with EU academics
December 3, 2012Manufacturing and Production Bayer, EU, Pharmacos, Sanofi
A group of top pharma multinationals have set up a public-private partnership dedicated to the development of manufacturing sustainable pharmaceuticals …
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
Xarelto gets new EU approval
November 21, 2012Sales and Marketing AF, Bayer, DVT, Xarelto
Bayer’s oral anticoagulant Xarelto has extended its licence in Europe to treat pulmonary embolism (PE) and prevent recurrent deep vein …
Bayer to acquire Schiff Nutrition
November 4, 2012Sales and Marketing Bayer, mergers and acquisitions
Bayer HealthCare is to buy US-based vitamins and nutritional supplements firm Schiff Nutrition International for $1.2 billion.The deal is part …
Bayer signs endometriosis pact
October 3, 2012Research and Development, Sales and Marketing Bayer, Evotec, endometriosis
Bayer HealthCare and Evotec have signed a five-year deal to look for three novel drugs to treat women with endometriosis. …
Latest content
